Evaluating the Efficacy and Safety of TACE Combined with Iodine-125 Brachytherapy Versus TACE Monotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine · 17.03.2026 · 15 (6) · 2267
DOI: 10.3390/jcm15062267 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.03.2026. Verfasst von Israa Alhashimi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Imaging Department, Hamad Medical Corporation, Doha P.O. Box 3488, Qatar. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar University.
Abstract (Originalsprache)
Background/Objectives: This review and meta-analysis assessed whether combining transarterial chemoembolization (TACE) with iodine-125 brachytherapy (I-125 brachytherapy) offers greater efficacy and safety than TACE alone in treating hepatocellular carcinoma (HCC).
Methods
PubMed, EMBASE, the Cochrane Library, Scopus, and Web of Science were searched for articles published between 1 January 2010 and 30 November 2023. Eligible studies compared TACE with and without I-125 brachytherapy from randomized controlled trials (RCTs) and non-randomized comparative studies published in English. The primary outcome was overall survival (OS) at 1, 2, and 3 years. The secondary outcomes included progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and adverse events. ROB-2 and ROBINS-I tools were used to assess study quality.
Results
Eighteen studies (n = 1872 patients) were included. All 18 studies originated from China, with the majority being retrospective cohorts (n = 16), one non-randomized prospective study, and one RCT. Compared with TACE alone, TACE + I-125 brachytherapy significantly improved OS at 1 year (OR = 3.64, 95% CI: 2.92–4.55), 2 years (OR = 3.93, 95% CI: 2.29–6.77), and 3 years (OR = 4.12, 95% CI: 2.24–7.56). The tumor response rates, including the ORR and DCR, were also significantly higher in the combination group. Subgroup analysis revealed that the survival benefit was maintained in studies without systemic chemotherapy (OR = 3.68, 95% CI: 2.89–4.70) and in studies with systemic chemotherapy (OR = 4.13, 95% CI: 1.69–10.09). Although larger effect estimates were observed with low-dose I-125 brachytherapy (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Imaging Department, Hamad Medical Corporation, Doha P.O. Box 3488, Qatar.
- College of Pharmacy, University of AI Maarif, Al Anbar 31001, Iraq.
- Department of Pharmacy, Aspetar Orthopedics and Sports Medicine Hospital, Doha P.O. Box 29222, Qatar.
- College of Health and Life Sciences, Hamad bin Khalifa University, Doha P.O. Box 34110, Qatar.
- College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
ORCID-Profile: Abeer Abdullah Hamid, Ali Barah, Mohamed Izham Mohamed Ibrahim
Förderung
- Qatar University
Zitieren
APA
Alhashimi, I., Hamid, A. A., Elkhalifa, D., Zoghoul, S., Barah, A., & Mohamed Ibrahim, M. I. (2026). Evaluating the Efficacy and Safety of TACE Combined with Iodine-125 Brachytherapy Versus TACE Monotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 15(6), 2267. https://doi.org/10.3390/jcm15062267
Vancouver
Alhashimi I, Hamid AA, Elkhalifa D, Zoghoul S, Barah A, Mohamed Ibrahim MI. Evaluating the Efficacy and Safety of TACE Combined with Iodine-125 Brachytherapy Versus TACE Monotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2026;15(6):2267. doi:10.3390/jcm15062267
BibTeX
@article{Alhashimi2026,
author = {Alhashimi, Israa and Hamid, Abeer Abdullah and Elkhalifa, Dana and Zoghoul, Sohaib and Barah, Ali and Mohamed Ibrahim, Mohamed Izham},
title = {Evaluating the Efficacy and Safety of TACE Combined with Iodine-125 Brachytherapy Versus TACE Monotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {6},
pages = {2267},
doi = {10.3390/jcm15062267}
}
EUVIMED